Neuland Laboratories Limited has completed its regulatory filing requirements by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed this compliance certificate on April 2, 2026, ensuring adherence to securities market regulations.

Regulatory Filing Details

The certificate was formally submitted to both major Indian stock exchanges where the company's shares are traded. Company Secretary Sarada Bhamidipati signed the submission letter on behalf of Neuland Laboratories Limited, addressing the filing to BSE Limited and The National Stock Exchange of India Ltd.

Registrar and Transfer Agent Certification

KFin Technologies Limited, serving as the company's Registrar and Share Transfer Agent, provided the necessary certification for this regulatory requirement. Senior Vice President Praveen Chaturvedi signed the certificates on April 1, 2026, confirming compliance with SEBI regulations.

The registrar issued separate certificates to both Central Depository Services (India) Limited (CDSL) and National Securities Depository Limited (NSDL), the two main depositories in India. These certificates confirm that all required details of securities dematerialized and rematerialized during the quarter have been properly furnished to the relevant stock exchanges.

Compliance Confirmation

The certification process ensures transparency in the dematerialization and rematerialization of securities during the specified quarter. KFin Technologies Limited certified that all necessary details regarding these transactions have been appropriately communicated to the stock exchanges where Neuland Laboratories' shares are listed.

This regulatory filing represents standard compliance practice for listed companies in India, ensuring proper documentation and reporting of securities transactions to maintain market transparency and investor protection.

Neuland laboratories has announced a leadership transition that marks a pivotal moment in the pharmaceutical contract development and manufacturing organization's growth trajectory. Saharsh Davuluri has assumed the role of Chief Executive Officer and Managing Director, effective immediately, as the company positions itself for an aggressive expansion phase in the global CDMO sector.

Leadership Transition and Strategic Vision

The leadership change represents a natural progression for the organization, with Saharsh bringing over 18 years of experience within the company. His appointment comes at a time when Neuland has demonstrated exceptional growth, having tripled its contract services revenues during the last 3 years. The new CEO will focus on positioning the company as a premier global API process development and commercial manufacturing specialist.

Saharsh has been instrumental in leading Neuland's transformation into a new chemical entity (NCE)-focused drug substance CDMO. Under his leadership, the company has secured a growing number of commercial manufacturing contracts with global innovator companies, reflecting rising demand for its expertise in process chemistry, scale-up, and reliable commercial supply.

Company Performance and Market Position

Neuland's recent success has been built on a growing reputation for scale-up of complex APIs and peptides. The company has established itself as a trusted partner for global innovators who bring their most complex chemistries and scale-up challenges to the organization.

The CDMO's growth strategy has been supported by its ability to accelerate development timelines through parallel development strategies while maintaining regulatory compliance. The company has filed over 1000 DMFs globally and offers more than 100 APIs across multiple therapeutic areas.

Expansion Plans and Future Outlook

Saharsh outlined ambitious plans for the company's future, emphasizing both immediate opportunities and long-term strategic goals. The new CEO highlighted the company's commitment to a four-phase expansion of commercial peptide capacity and plans to double process development capabilities.

The company is embarking on an aggressive expansion phase and could, pending customer approvals, secure several more commercial NCE contracts, including peptides, over the next one to two years. Neuland invested in a new commercial scale peptide facility in 2026 and is opening a large, dedicated R&D process development centre in Hyderabad.

Strategic Focus Areas

The leadership transition comes with a clear strategic focus on several key areas that will drive future growth:

• Complex Chemistry Expertise: Leveraging the company's reputation for specialist process chemistries and process innovation
• Accelerated Development: Maintaining competitive advantage through shortened development timelines
• Commercial Supply Reliability: Ensuring consistent CMC delivery to biotech and big pharma partners
• Peptide Manufacturing: Expanding capabilities in the growing peptides market
• Global CDMO Positioning: Ambition to become one of the world's top five API-focused CDMOs over the next decade

Saharsh emphasized that the company's investment approach is built around the innovation pipelines of its customers, structuring teams and capabilities to meet evolving development needs of partners. This customer-centric approach has been a key driver behind the rapidly growing number of biotech and big pharma partnerships.

The leadership change positions Neuland Laboratories to capitalize on the growing demand in the CDMO sector while maintaining its focus on complex API development and manufacturing excellence.